Accurate diagnosis and prognosis of renal deterioration are of utmost interest for patient healthcare. Unfortunately, current clinical measurements and biochemical markers of the renal function are providing poor outcome of disease onset. Therefore, novel and more reliable biomarkers are needed to allow early risk stratification of the patients suffering from Autosomal polycystic kidney disease (ADPKD). Mass spectrometry approaches on various biological specimens have shown to be beneficial in screening putative diagnostics and prognostics biomarkers. With the usage of the advances in mass spectrometry (MS)-based technology, nowadays, utilization of multidimensional marker panels carries the potential to improve the clinical diagnostic and prognostic value for many diseases including ADPKD. Additionally, obtaining correct peptide sequence information may provide a link to the pathophysiology of the underlying diseases and discover novel therapeutic targets for personalized healthcare of patients.
Patients diagnosed with autosomal polycystic kidney disease (ADPKD) have an incidence between 1:400 and 1:1000 in the general population. This tubular disease is characterized by a significant increase in serum creatinine levels typically followed by a rapid decline of glomerulus filtration rate (GFR) and progression to end stage renal disease (ESRD), where severe complication occurs and hamper a reliable clinical assessment. The symptoms of renal dysfunction often do not appear until subsequent kidney damage occur, and management of such patients remain challenging. Standard medical drugs like rigorous blood pressure control using renin angiotensin-aldosterone (RAAS)-blockade, angiotensin-covering enzyme (ACE) and angiotensin receptor blockers (ARBs) have been shown to ease down the episodes of renal injury and delay disease progression. Several treatment strategies have been developed for ADPKD patients, but their success is still controversial. One part could be attributed to the lack of knowledge of early molecular mechanisms associated with the disease onset and the complex pathophysiological processes. Therefore, identification and characterization of novel and more reliable non-invasive biomarkers for early risk stratification of the patients being likely exposed to progress toward ESRD or renal failure could be of utmost interest for improvement of daily clinical practice.
The aim of this research topic is to improve our current understanding of the molecular mechanisms observed in ADPKD through more in depth assessing of the proteomic profiles and their molecular function. The focus is given on several key points: a) Assessment and evaluation of proteomic datasets in animal models for identification of potential targets b) Screening of clinical patient cohorts for characterization and development of multi-marker panels for diagnosis, prognosis and monitoring of disease progression c) computational analysis for evaluation of large datasets from the proteomics experiments and mapping molecular pathways related to disease pathophysiology d) Identification of novel proteomic targets for drug development. Researchers are encourage to send original research, rapid communication, review article, and case study.
Keywords:
proteomics, Autosomal polycystic kidney disease (ADPKD), end stage renal disease (ESRD), diagnostic biomarkers, prognostic biomarkers, application
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
Accurate diagnosis and prognosis of renal deterioration are of utmost interest for patient healthcare. Unfortunately, current clinical measurements and biochemical markers of the renal function are providing poor outcome of disease onset. Therefore, novel and more reliable biomarkers are needed to allow early risk stratification of the patients suffering from Autosomal polycystic kidney disease (ADPKD). Mass spectrometry approaches on various biological specimens have shown to be beneficial in screening putative diagnostics and prognostics biomarkers. With the usage of the advances in mass spectrometry (MS)-based technology, nowadays, utilization of multidimensional marker panels carries the potential to improve the clinical diagnostic and prognostic value for many diseases including ADPKD. Additionally, obtaining correct peptide sequence information may provide a link to the pathophysiology of the underlying diseases and discover novel therapeutic targets for personalized healthcare of patients.
Patients diagnosed with autosomal polycystic kidney disease (ADPKD) have an incidence between 1:400 and 1:1000 in the general population. This tubular disease is characterized by a significant increase in serum creatinine levels typically followed by a rapid decline of glomerulus filtration rate (GFR) and progression to end stage renal disease (ESRD), where severe complication occurs and hamper a reliable clinical assessment. The symptoms of renal dysfunction often do not appear until subsequent kidney damage occur, and management of such patients remain challenging. Standard medical drugs like rigorous blood pressure control using renin angiotensin-aldosterone (RAAS)-blockade, angiotensin-covering enzyme (ACE) and angiotensin receptor blockers (ARBs) have been shown to ease down the episodes of renal injury and delay disease progression. Several treatment strategies have been developed for ADPKD patients, but their success is still controversial. One part could be attributed to the lack of knowledge of early molecular mechanisms associated with the disease onset and the complex pathophysiological processes. Therefore, identification and characterization of novel and more reliable non-invasive biomarkers for early risk stratification of the patients being likely exposed to progress toward ESRD or renal failure could be of utmost interest for improvement of daily clinical practice.
The aim of this research topic is to improve our current understanding of the molecular mechanisms observed in ADPKD through more in depth assessing of the proteomic profiles and their molecular function. The focus is given on several key points: a) Assessment and evaluation of proteomic datasets in animal models for identification of potential targets b) Screening of clinical patient cohorts for characterization and development of multi-marker panels for diagnosis, prognosis and monitoring of disease progression c) computational analysis for evaluation of large datasets from the proteomics experiments and mapping molecular pathways related to disease pathophysiology d) Identification of novel proteomic targets for drug development. Researchers are encourage to send original research, rapid communication, review article, and case study.
Keywords:
proteomics, Autosomal polycystic kidney disease (ADPKD), end stage renal disease (ESRD), diagnostic biomarkers, prognostic biomarkers, application
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.